USRM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
USRM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, US Stem Cell's enterprise value is $9.01 Mil. US Stem Cell's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 was $0.08 Mil. Therefore, US Stem Cell's EV-to-Revenue for today is 109.83.
The historical rank and industry rank for US Stem Cell's EV-to-Revenue or its related term are showing as below:
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-24), US Stem Cell's stock price is $0.0001. US Stem Cell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00. Therefore, US Stem Cell's PS Ratio for today is .
The historical data trend for US Stem Cell's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
EV-to-Revenue | Get a 7-Day Free Trial | 1.68 | 3.37 | 46.14 | 54.72 | 146.18 |
US Stem Cell Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
EV-to-Revenue | Get a 7-Day Free Trial | 54.72 | 99.05 | 92.25 | 146.29 | 146.18 |
For the Biotechnology subindustry, US Stem Cell's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, US Stem Cell's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where US Stem Cell's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
US Stem Cell's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 9.006 | / | 0.082 | |
= | 109.83 |
US Stem Cell's current Enterprise Value is $9.01 Mil.
US Stem Cell's Revenue for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.08 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
US Stem Cell (OTCPK:USRM) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
US Stem Cell's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 0.0001 | / | 0 | |
= |
US Stem Cell's share price for today is $0.0001.
US Stem Cell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of US Stem Cell's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Murphy William P Jr | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Gregory Knutson | director | 14855 ABERDEN STREET NE, HAM LAKE MN 55304 |
Mark P Borman | director | 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410 |
Charles A Hart | director | 19345 RHINESTONE STREET NW, ANOKA MN 55303 |
Sheldon T. Anderson | director | 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149 |
Kristin C Comella | officer: Chief Science Officer | 1310 LEEWARD WAY, WESTON FL 33327 |
A Jones Lee | director | 54 LOCKE LAKE RD, FRIDLEY MN 55432 |
Karl Groth | director | 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029 |
Matthew J Fendrich | officer: Vice President,Sales&Marketing | 482 PEACOCK LANE SOUTH, JUPITER FL 33458 |
Alan P Timmins | director | 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660 |
Bruce C Carson | director | 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448 |
Howard J Leonhardt | director, 10 percent owner, officer: Executive Chairman & CTO | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Bromley R Scott | officer: VP of Public Relations | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Richard Iii Spencer | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
Mike Tomas | director | 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325 |
From GuruFocus
By PRNewswire PRNewswire • 07-10-2018
By PRNewswire PRNewswire • 05-03-2018
By PRNewswire PRNewswire • 03-14-2019
By ACCESSWIRE ACCESSWIRE • 09-30-2020
By PRNewswire PRNewswire • 10-09-2018
By PRNewswire PRNewswire • 05-10-2018
By PRNewswire PRNewswire • 05-08-2019
By ACCESSWIRE ACCESSWIRE • 10-18-2021
By ACCESSWIRE ACCESSWIRE • 01-19-2021
By PRNewswire PRNewswire • 01-15-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.